Tubulis scores Series A

Munich, Germany-based Tubulis, a developer of protein-drug conjugates, has secured 10.7 million euros in Series A funding.

21 July 2020•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles